

Market Applicability/Effective Date															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

Fluoroquinolone Ophthalmics

Override(s)	Approval Duration
Prior Authorization Quantity Limit	One time only

Medications	Quantity Limit
Besivance (besifloxacin) Moxeza (moxifloxacin) Vigamox – Brand – use MSB criteria Zymaxid – Brand – use MSB criteria	May be subject to quantity limit

APPROVAL CRITERIA

Requests for a select fluoroquinolone ophthalmic agent [Besivance (besifloxacin), Moxeza (moxifloxacin)] may be approved if the following criteria is met:

- I. Individual has a diagnosis of bacterial conjunctivitis; **AND**
- II. Individual has had a trial [duration of at least 3 days (AAO 2013), (medication samples/coupons/discount cards are excluded from consideration as a trial)] and an inadequate response to one of the following generic ophthalmic antimicrobial agents in the previous 30 days:
 - A. Ciprofloxacin (generic Ciloxan); **OR**
 - B. Ofloxacin (generic Ocuflax); **OR**
 - C. Erythromycin (generic Ilotycin); **OR**
 - D. Gentamycin (generic Garamycin); **OR**
 - E. Polymixin B/trimethoprim (generic Polytrim); **OR**
 - F. Bacitracin/polymixin B (generic Polysporin); **OR**
 - G. Sodium Sulfacetamide (generic Bleph 10); **OR**
 - H. Tobramycin (generic Tobrex); **OR**
 - I. Levofloxacin (generic Quixin); **OR**
 - J. Moxifloxacin (generic Vigamox); **OR**
 - K. Gatifloxacin (generic Zymaxid);
- OR**
- III. Individual is using as prophylaxis to prevent endophthalmitis following cataract surgery (AAO 2011; Chang et al, 2015; Bratzler et. al, 2013) **OR**
- IV. Isolates have been identified which indicate resistance to the preferred first line ophthalmic fluoroquinolones (such as, ciprofloxacin, ofloxacin, or levofloxacin) and an increased susceptibility to, Besivance or Moxeza.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability/Effective Date															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	N/A	N/A	X	N/A	X	X	X	X	X	X	N/A	N/A	X

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2017.
 URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed January 30, 2017.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.